Zoledronic Acid

Research use only, not for human use.

Zoledronic acid induces apoptosis in osteoclasts by inhibiting enzymes of the mevalonate pathway and preventing the isoprenylation of small GTP-binding proteins such as Ras and Rho.

Zoledronic acid induces apoptosis in osteoclasts by inhibiting enzymes of the mevalonate pathway and preventing the isoprenylation of small GTP-binding proteins such as Ras and Rho.(In Vitro):Zoledronic Acid (0.1-1 μM; 48 hours) increases receptor activator of nuclear factor kB ligand (RANKL) and sclerostin mRNA expressions in osteocyte-like MLO-Y4 cells.Zoledronic Acid increases the expression of osteoclastogenesis supporting factor from MLO-Y4 cells.Zoledronic Acid enhances the RANKL expression via IL-6/ JAK2/STAT3 pathway in MLO-Y4 cells.Zoledronic acid inhibits osteoclast differentiation and function through the regulation of NF-κB and JNK signalling pathways.Zoledronic Acid (10-100 μM; 1-7 days) markedly reduces the viability of MC3T3-E1 cells.Zoledronic Acid (10-100 μM; 1-7 days) induces apoptosis in MC3T3-E1 cells.Zoledronic Acid (10-100 μM; 4 days) inhibits cell viability due to the induction of apoptosis.Zoledronic Acid exerts inhibitory effects on the differentiation and maturation of MC3T3-E1 cells at concentrations <1 μM.(In Vivo):Zoledronic Acid (0.05 mg/kg; i.p.; weekly; for 3 weeks) increases bone mineral density and content.Zoledronic Acid (0.5-1 mg/kg; i.p.; weekly; for 3 weeks) inhibits both osteoclast and osteoblasts function and bone remodeling in vivo interfering with bone mechanical properties.

Zoledronic Acid (0.1-1 μM; 48 hours) increases receptor activator of nuclear factor kB ligand (RANKL) and sclerostin mRNA expressions in osteocyte-like MLO-Y4 cells.Zoledronic Acid increases the expression of osteoclastogenesis supporting factor from MLO-Y4 cells.Zoledronic Acid enhances the RANKL expression via IL-6/ JAK2/STAT3 pathway in MLO-Y4 cells.Zoledronic acid inhibits osteoclast differentiation and function through the regulation of NF-κB and JNK signalling pathways.Zoledronic Acid (10-100 μM; 1-7 days) markedly reduces the viability of MC3T3-E1 cells.Zoledronic Acid (10-100 μM; 1-7 days) induces apoptosis in MC3T3-E1 cells.Zoledronic Acid (10-100 μM; 4 days) inhibits cell viability due to the induction of apoptosis.Zoledronic Acid exerts inhibitory effects on the differentiation and maturation of MC3T3-E1 cells at concentrations <1 μM.Cell Viability Assay Cell Line:MC3T3-E1 cells Concentration:0.01 μM , 0.1 μM, 1 μM, 10 μM, 100 μMIncubation Time:1 day, 3 days, 5 days, 7 days Result:Reduced cells viability at 10 μM and 100 μM.Apoptosis Analysis Cell Line:MC3T3-E1 cells Concentration:0.01 μM , 0.1 μM, 1 μM, 10 μM, 100 μM Incubation Time:1 days, 4 days, 7 days Result:Increased the number of early apoptotic cells and late apoptotic or necrotic cells at dose-dependent and time-dependent (high concentrations).Western Blot Analysis Cell Line:MC3T3-E1 cells Concentration:0.01 μM , 0.1 μM, 1 μM, 10 μM, 100 μM Incubation Time:4 days Result:Down-regulated the protein level of inactive caspase-3 and up-regulated the protein level of active caspase-3 at the concentrations of 10 and 100 μM.

Zoledronic Acid (0.05 mg/kg; i.p.; weekly; for 3 weeks) increases bone mineral density and content.Zoledronic Acid (0.5-1 mg/kg; i.p.; weekly; for 3 weeks) inhibits both osteoclast and osteoblasts function and bone remodeling in vivo interfering with bone mechanical properties. Animal Model:Five-week-old C57BL6 mice Dosage:0.05 mg/kg, 0.5 mg/kg, 1 mg/kg Administration:Intraperitoneal injection, weekly, for 3 weeks Result:Inhibited both osteoclast and osteoblasts function and bone remodeling at 0.5 mg/kg and 1 mg/kg.

Orazol | Reclast | Zoledronate | Zoledronic acid

Cell Cycle/DNA Damage

Rho

Rho

Cancer

——

118072-93-8

272.09

C5H10N2O7P2

>98% (HPLC)

0.1M NaOH (aq): 40 mg/ml; DMSO: 0.004 mg/mL (0.01 mM)

OC(P(O)(O)=O)(P(O)(O)=O)CN1C=CN=C1

Phosphonic acid, (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bis-

(-20℃)

With Ice Pack

≥ 2 years